NEW YORK, /PRNewswire/ - According to a report published by Allied Market Research, the global cancer therapeutics market was valued at USD 81 Billion in 2016 and is expected to reach about USD 179 Billion by 2023 while growing at a compound annual growth rate (CAGR) of 11.9%. Demand for cancer therapy increases as the number of people who have cancer is rising rapidly. The report indicated that the market is segmented based on application, top-selling drugs, and region. Traditional cancer therapeutics include chemotherapy and oncology drugs treatment. However, high cost of oncology drug development may restrain the growth of oncology drugs treatment market. Regen BioPharma, Inc. (OTC :RGBP ), Celldex Therapeutics, Inc. (NASDAQ :CLDX ), Onconova Therapeutics, Inc. (NASDAQ :ONTX ), aTyr Pharma, Inc. (NASDAQ :LIFE ), OncoSec Medical Incorporated (NASDAQ :ONCS )
Cancer immunotherapy has emerged as a new treatment for cancer. According to research from Grand View Research, the global cancer immunotherapy market size was valued at USD 40.7 Billion in 2016. Rising R&D in cancer immunotherapy and increases in the number of approvals for new immune therapeutic drugs are expected to drive the immunotherapy market. New immunotherapeutic options include immunomodulators and CAR-T cell therapy, which are in the pipeline and are being tested for their ability to provide better cancer treatment. The report indicated most of the cancer immunotherapy drugs have been used in the treatment of non-small cell lung cancer, breast cancer, and prostate cancer.
Regen BioPharma, Inc. (OTCQB: RGBP) earlier this month announced breaking news that it, "has identified a series of small molecule drugs that inhibit NR2F6. Regen's screening process demonstrated that its recently-identified, novel chemical compounds appear to inhibit NR2F6 and thus can potentially be developed for treating cancer.
The NR2F6 nuclear receptor has been identified as a potentially important immune cell inhibitor (an immune checkpoint), which may lead to developing therapies for treating cancers. Therapies that manipulate NR2F6 also show potential to act as cancer stem cell differentiators, transforming cancer stem cells into normal cells.
The NR2F6 program at Regen aims to identify antagonists of NR2F6 in order to unleash the cancer-killing potential of a patient's own immune system as well as identify agonists which should suppress the immune system in diseases where the immune system is over-activated, such as autoimmunity.
"We have identified a handful of compounds, representing three different structural classes, that inhibit NR2F6 in our primary screening assay," says Harry Lander, Ph.D., MBA, President and Chief Scientific Officer of Regen. "They exhibited a dose-dependent inhibitory effect on NR2F6 without cytotoxicity. Our next steps will focus on determining what effect they have on human immune cells."
David Koos, Ph.D., Chairman & CEO of Regen BioPharma Inc. added, "This is exciting for Regen to reach this point in its goal for developing therapies that treat cancer. These compounds should provide us the basis to further refine our screening for successful antagonists in the development of immunologically-based cancer therapies."
Correction: Regen BioPharma previously disclosed, in error, that "inhibiting NR2F6 is believed to provide potential therapies for treating autoimmunity." The statement should read: "Activating NR2F6 potentially leads to inhibiting the immune system and should lead to therapies for treating autoimmunity diseases such as lupus."
Celldex Therapeutics, Inc. (NASDAQ :CLDX ) is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. The Company's pipeline includes immunotherapies and other targeted biologics derived from a broad set of complementary technologies which have the ability to engage the human immune system and/or directly inhibit tumors to treat specific types of cancer or other diseases. Last month, the Company reported business and financial highlights for the second quarter ended June 30th, 2018. Cash, cash equivalents and marketable securities as of June 30th, 2018 were USD 114.0 Million compared to USD 123.2 Million as of March 31st, 2018. Research and development (R&D) expenses were USD 21.4 Million in the second quarter of 2018 and USD 43.3 Million for the six months ended June 30th , 2018, compared to USD 25.0 Million and USD 50.8 Million for the comparable periods in 2017.
Onconova Therapeutics, Inc. (NASDAQ :ONTX ) is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS). In late August, the Company announced that its commercial partner, Pint Pharma GmbH, will assist in expanding access to clinical trials studying rigosertib, a novel and targeted anti-cancer compound currently in a Phase 3 study for the treatment of MDS, to several selected sites across South America. Pint Pharma is a European-based pharmaceutical company focused on the development, registration and commercialization of specialty-based treatments for the Latin American market and has successfully participated in clinical trials for hematological cancers.
aTyr Pharma, Inc. (NASDAQ :LIFE ) is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways. Last month, the Company announced operating results for the second quarter ended June 30th, 2018. In June 2018, aTyr announced results of its Phase 1, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, immunogenicity and pharmacokinetics (PK) of intravenous ATYR1923 in 36 healthy volunteers. In the fourth quarter of 2018, aTyr plans to initiate a Phase 1b/2a multiple-ascending dose, placebo-controlled, first-in-patient study with ATYR1923 for the treatment of patients with immune-mediated interstitial lung disease. Research and development expenses were USD 6.5 Million and USD 8.4 Million for the three months ended June 30th, 2018 and 2017, respectively. Research and development expenses were USD 12.6 Million and USD 17.6 Million for the six months ended June 30th , 2018 and 2017, respectively.
OncoSec Medical Incorporated (NASDAQ :ONCS ) is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. Earlier this month, the Company announced that it has secured a USD 15 Million investment from Alpha Holdings, Inc. as part of a value-focused, fundamental strategic investment centered on the clinical development of OncoSec's lead immunotherapy product candidate, TAVO (tavokinogene telseplasmid). TAVO enables the intratumoral delivery of DNA-based interleukin-12 (IL-12), a naturally occurring protein with powerful immune-stimulating functions. Alpha Holdings is a leading Korean company engaged in the design, development, service and manufacture of system semiconductors, as well as the development of biotechnologies and thermal compound materials. Since 2002, Alpha Holdings has successfully carried out many projects as a major partner of Samsung Advanced Foundry Eco-system (SAFE) of Samsung Electronics.
Subscribe Now - Watch us report LIVE https://www.youtube.com/FinancialBuzzMedia
Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz
Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz
Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/
For further information: